RxDoctor Payments Data

David Guerrero, MD

Family Medicine · San Antonio, TXNPI 1265561849

Payments from drug & device makers

$7,923in general payments, 2019–2025

Across 528 payments — averaging $15.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Johnson & Johnson$752
  • Lilly USA, LLC$710
  • Astellas Pharma US Inc$550
  • AstraZeneca$442
  • Merck$351
  • plus $4K from 38 others

What the payments were for

  • Food & beverage$7,63196%
  • Education$2333%
  • Gifts$591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,923 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$71,756
Medicare patients
157
Services billed
872

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$125,610
JanuviaSitagliptin Phosphate106$120,087
TradjentaLinagliptin78$86,241
JardianceEmpagliflozin49$58,631
EliquisApixaban35$57,913
FarxigaDapagliflozin Propanediol26$38,735
MounjaroTirzepatide27$31,420
RexultiBrexpiprazole17$27,586
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$22,449
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$21,697
XareltoRivaroxaban17$17,276
MyrbetriqMirabegron16$16,501
Tresiba Flextouch U-100Insulin Degludec18$16,393
Tresiba Flextouch U-200Insulin Degludec14$14,875
Rosuvastatin Calcium947$9,504

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimTradjenta, Jardiance, Jentadueto$12$150,238140 claims
Novo NordiskOzempic$1,268$125,61095 claims
MerckJanuvia$351$120,087106 claims
PfizerEliquis$162$57,91335 claims
AstraZenecaFarxiga, Symbicort$442$42,37141 claims
Lilly USA, LLCMounjaro$710$31,42027 claims
Otsuka America Pharmaceutical, Inc.Rexulti$238$27,58617 claims
Johnson & JohnsonXarelto$752$17,27617 claims
Astellas Pharma US IncMyrbetriq$550$16,50116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →